How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
The consensus price target hints at a 34.2% upside potential for Keros Therapeutics (KROS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How this was made

The 30-second read
Why it matters
While the target suggests significant upside, actual stock movement depends on broader market conditions and company-specific developments.
Market read
The news is relevant for biotech investors and traders focusing on small-cap growth stocks with upcoming earnings revisions.
What to watch
Potential regulatory hurdles, clinical trial outcomes, or macroeconomic factors could negate the upside potential.
Background
Keros Therapeutics (KROS) has received analyst target upgrades, indicating anticipated growth.
Ticker impact
High relevance due to recent analyst target and earnings revision trends.
Moderate upward movement in the near term, approximately 10-15%, contingent on continued earnings revision trends.
The upward trend in earnings estimates indicates investor optimism, but the low relevance score (0.2842) and the modest sentiment (bullish at 38.66%) suggest caution. External factors and market conditions could influence actual performance.
Market effects
Potential positive impact on biotech and life sciences sectors, possibly boosting related stocks.
Limited to North American markets, where KROS is primarily traded.
Minimal, as the news pertains to a specific biotech company with niche relevance.
Counterpoint
Earnings estimate revisions may be overly optimistic; empirical research suggests limited effectiveness of such metrics in predicting stock performance.
Key entities
- CompanyKeros Therapeutics
Biotech firm focusing on therapies for hematology and oncology.
- AnalystsWall Street Analysts
Financial analysts providing target price estimates and revisions.





